Black Diamond Therapeutics Inc. (BDTX) Financial Statements (2024 and earlier)

Company Profile

Business Address ONE MAIN STREET, 14TH FLOOR
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments131,400122,807209,786315,067154,666
Cash and cash equivalents56,22134,31565,79934,605154,666
Short-term investments75,17988,492143,987280,462 
Restricted cash and investments  1,1681,2231,22355
Other undisclosed current assets2,6343,7314,6943,264993
Total current assets:134,034127,706215,703319,554155,714
Noncurrent Assets
Operating lease, right-of-use asset21,98024,79427,7058,402 
Property, plant and equipment1,7302,5873,035385164
Restricted cash and investments8231,1681,2231,22355
Deferred costs     2,303
Other noncurrent assets   1610659
Total noncurrent assets:24,53328,54931,97910,1162,581
TOTAL ASSETS:158,567156,255247,682329,670158,295
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19,64615,26123,64214,2184,863
Accounts payable2,3241,8774,1072,5381,964
Accrued liabilities17,32213,38419,53511,6802,899
Total current liabilities:19,64615,26123,64214,2184,863
Noncurrent Liabilities
Long-term debt and lease obligation:   28,1407,694 
Liabilities, other than long-term debt22,18525,299  16
Operating lease, liability22,18525,29928,1407,694 
Derivative instruments and hedges, liabilities     16
Other undisclosed noncurrent liabilities   (28,140)(7,694) 
Total noncurrent liabilities:22,18525,29928,1407,69416
Total liabilities:41,83140,56051,78221,9124,879
Temporary equity, carrying amount     200,573
Equity
Equity, attributable to parent116,736115,695195,900307,758(47,157)
Common stock75551
Additional paid in capital534,187452,503440,129425,3633,812
Accumulated other comprehensive income (loss)(27)(1,824)(414)614 
Accumulated deficit(417,431)(334,989)(243,820)(118,224)(50,970)
Total equity:116,736115,695195,900307,758(47,157)
TOTAL LIABILITIES AND EQUITY:158,567156,255247,682329,670158,295

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues1,138 1024 
Sublease income1,138    
Gain on disposition of assets for financial service operations   1024 
Gross profit:1,138 1024 
Operating expenses(86,460)(92,828)(126,872)(69,570)(29,332)
Other undisclosed operating loss(1,138) (10)(24) 
Operating loss:(86,460)(92,828)(126,872)(69,570)(29,332)
Nonoperating income (expense)4,0183,9091,2762,316(5,926)
Investment income, nonoperating1,9242,0313,4644,041461
Other nonoperating income (expense)2,094(354)(2,188)(1,724)6
Interest and debt expense    (1) 
Loss from continuing operations before equity method investments, income taxes:(82,442)(88,919)(125,596)(67,255)(35,258)
Loss from equity method investments  (2,250)   
Loss from continuing operations:(82,442)(91,169)(125,596)(67,255)(35,258)
Loss before gain (loss) on sale of properties:(125,596)(67,255)(35,258)
Net loss:(82,442)(91,169)(125,596)(67,255)(35,258)
Other undisclosed net income attributable to parent    1 
Net loss available to common stockholders, diluted:(82,442)(91,169)(125,596)(67,254)(35,258)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(82,442)(91,169)(125,596)(67,255)(35,258)
Comprehensive loss:(82,442)(91,169)(125,596)(67,255)(35,258)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,797(1,410)(1,028)615 
Comprehensive loss, net of tax, attributable to parent:(80,645)(92,579)(126,624)(66,640)(35,258)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: